| scholarly article | Q13442814 |
| P2093 | author name string | Bulent Erdogan | |
| Esma Turkmen | |||
| Hilmi Kodaz | |||
| Ilhan Hacibekiroglu | |||
| Irfan Cicin | |||
| Sernaz Uzunoglu | |||
| Hilmi Tozkir | |||
| Dogan Albayrak | |||
| P2860 | cites work | The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website | Q24645514 |
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab | Q27851587 | ||
| Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum | Q28262150 | ||
| The KRAS oncogene: past, present, and future | Q28280286 | ||
| Genetic alterations during colorectal-tumor development | Q28281200 | ||
| Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes | Q28307762 | ||
| Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study | Q28348036 | ||
| European cancer mortality predictions for the year 2014. | Q34661464 | ||
| KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients | Q35144608 | ||
| Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer | Q36396396 | ||
| Dietary folate intake and k-ras mutations in sporadic colon and rectal cancer in The Netherlands Cohort Study | Q38444801 | ||
| K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study | Q38452428 | ||
| K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. | Q42833403 | ||
| Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer | Q43292375 | ||
| Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab | Q43959224 | ||
| KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab | Q46903224 | ||
| Predominance of G to A codon 12 mutation K-ras gene in Dukes' B colorectal cancer | Q54328751 | ||
| DNA Ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study | Q60684277 | ||
| Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas | Q72428444 | ||
| Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer | Q73122770 | ||
| Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia | Q87537926 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 179-184 | |
| P577 | publication date | 2014-10-27 | |
| P1433 | published in | Molecular and Clinical Oncology | Q27725125 |
| P1476 | title | Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors | |
| P478 | volume | 3 |
| Q33739940 | Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation |
| Q35592388 | Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft |
| Q30384542 | Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. |
| Q64110416 | Impact of primary colorectal Cancer location on the KRAS status and its prognostic value |
| Q37211434 | KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer |
| Q26996463 | Molecular Technologies in the Clinical Diagnostic Laboratory |
| Q50097873 | Mutations of key driver genes in colorectal cancer progression and metastasis |
| Q92125806 | Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis |
| Q36175288 | RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres |
| Q42160986 | Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer |
Search more.